S&P Futures
4,171.00+13.25(+0.32%)Dow Futures
34,368.00+112.00(+0.33%)Nasdaq Futures
13,378.25+74.75(+0.56%)
PerkinElmer, Inc. (PKI)
Chart Events
Performance Outlook
| Previous Close | 143.56 |
| Open | 143.50 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 143.15 - 144.83 |
| 52 Week Range | 91.26 - 162.70 |
| Volume | 621,093 |
| Avg. Volume | 990,395 |
| Market Cap | 16.055B |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | 14.98 |
| EPS (TTM) | 9.56 |
| Earnings Date | Jul 26, 2021 - Jul 30, 2021 |
| Forward Dividend & Yield | 0.28 (0.20%) |
| Ex-Dividend Date | Jul 15, 2021 |
| 1y Target Est | 157.57 |
Fair Value
Related Research
- Zacks
If You Invested $1000 in PerkinElmer a Decade Ago, This is How Much It'd Be Worth Now
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
- Benzinga
PerkinElmer To Acquire UK-Based In-Vitro Diagnostics Company For $155M
PerkinElmer Inc (NYSE: PKI) has agreed to acquire the U.K.-listed Immunodiagnostic Systems Holdings Plc's (IDS) in an all-cash transaction of approximately $155 million (£110 Million). The transaction has a total enterprise value of approximately $124 million (£88 Million) and is expected to close early in the third quarter of 2021. Through this acquisition, PerkinElmer could grow its immunodiagnostics segment and the overall Diagnostics business. IDS' portfolio will integrate within Euroimmun, a PerkinElmer company, since 2017. It provides autoimmune testing and is an emerging force in infectious disease, allergy, and molecular genetic testing. Headquartered in Boldon, the United Kingdom, IDS is a provider of in-vitro diagnostic solutions and has 300 global employees. In terms of financial impact, PerkinElmer expects the acquisition to be modestly accretive to non-GAAP earnings in year one following the close. Last week, PerkinElmer announced to acquire Nexcelom Bioscience for 0 million, to expand its capabilities in cell biology. Price Action: PKI shares closed at $143.56 on Friday. See more from BenzingaClick here for options trades from BenzingaPerkinElmer Expands Into Cell Biology With 0M Nexcelom Bioscience Acquisition© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Business Wire
PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC
PerkinElmer, Inc. (NYSE: PKI) ("PerkinElmer") and Immunodiagnostic Systems Holdings PLC (LSE: IHS) ("IDS") are pleased to announce that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire IDS for approximately $155 million (£110 Million). The transaction has a total enterprise value of approximately $124 million (£88 Million) and is expected to close early in the third quarter of 2021, subject to approvals from the shareholders of IDS, sanction by the High Court of Justice in England and Wales and other customary closing conditions for a public takeover in the United Kingdom.
